Alberta Transplant Applied Genomics Centre Edmonton AB Canada

Department of Immunogenetics Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Nephrology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Pathology Institute for Clinical and Experimental Medicine Prague Czech Republic

Division of Nephrology and Dialysis Department of Medicine 3 Medical University Vienna Vienna Austria

Transplant Laboratory Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Loupy A, Lefaucheur C. Antibody-mediated rejection of solid-organ allografts. N Engl J Med. 2018;379:1150–1160. PubMed

Schinstock CA, Mannon RB, Budde K, et al. . Recommended treatment for antibody-mediated rejection after kidney transplantation: the 2019 expert consensus from the Transplantation Society Working Group. Transplantation. 2020;104:911–922. PubMed PMC

Heeger PS, Haro MC, Jordan S. Translating B cell immunology to the treatment of antibody-mediated allograft rejection. Nat Rev Nephrol. 2024;20:218–232. PubMed

Bailly E, Macedo C, Ossart J, et al. . Interleukin-21 promotes type-1 activation and cytotoxicity of CD56(dim)CD16(bright) natural killer cells during kidney allograft antibody-mediated rejection showing a new link between adaptive and innate humoral allo-immunity. Kidney Int. 2023;104:707–723. PubMed PMC

Diebold M, Vietzen H, Heinzel A, et al. . Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation. Am J Transplant. 2024;24:743–754. PubMed

de Nattes T, Kaveri R, Farce F, et al. . Daratumumab for antibody-mediated rejection: Is it time to target the real culprit? Am J Transplant. 2023;23:1990–1994. PubMed

Zhu L, Guo Z, Zhao D, et al. . Case report: Daratumumab for treatment of refractory late or chronic active antibody-mediated rejection in renal allograft recipients with high levels of de novo donor-specific antibodies. Front Immunol. 2022;13:1087597. PubMed PMC

Doberer K, Klager J, Gualdoni GA, et al. . CD38 antibody daratumumab for the treatment of chronic active antibody-mediated kidney allograft rejection. Transplantation. 2021;105:451–457. PubMed

Slatinska J, Honsova E, Burgelova M, et al. . Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience. Ther Apher Dial. 2009;13:108–112. PubMed

Halloran PF, Madill-Thomsen KS, Reeve J. The molecular phenotype of kidney transplants: insights from the MMDx project. Transplantation. 2024;108:45–71. PubMed PMC

Madill-Thomsen KS, Bohmig GA, Bromberg J, et al. ; the INTERCOMEX Investigators. Donor-specific antibody is associated with increased expression of rejection transcripts in renal transplant biopsies classified as no rejection. J Am Soc Nephrol. 2021;32:2743–2758. PubMed PMC

Naesens M, Roufosse C, Haas M, et al. . The Banff 2022 Kidney Meeting Report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant. 2024;24:338–349. PubMed

Transcriptomic Signatures of Antibody-mediated Rejection in Early Biopsies With Negative Histology in HLA-incompatible Kidney Transplantation